150,553 Pfizer Inc. $PFE Shares Acquired by Farther Finance Advisors LLC

Key Points

• Farther Finance Advisors increased its Pfizer stake by 38.1%, acquiring 150,553 additional shares to bring its holdings to 545,850 shares valued at approximately $15.6 million. Institutional investors collectively own 68.36% of Pfizer.
• Analysts maintain a consensus “Hold” rating with an average price target of $28.61, modestly above Pfizer’s reported share price of $27.82.
• Pfizer exceeded quarterly earnings and revenue expectations, reporting $0.77 in EPS and $15.03 billion in revenue. The company also declared a quarterly dividend of $0.43 per share, implying a 6.2% annualized yield, though its payout ratio remains elevated at 226.32%.

Farther Finance Advisors LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 38.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 545,850 shares of the biopharmaceutical company's stock after buying an additional 150,553 shares during the quarter. Farther Finance Advisors LLC's holdings in Pfizer were worth $15,568,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. increased its position in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp boosted its holdings in Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. Bank of New York Mellon Corp grew its position in shares of Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company's stock worth $1,393,739,000 after purchasing an additional 3,999,646 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Pfizer during the second quarter worth approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company's stock valued at $1,022,606,000 after buying an additional 293,029 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Guggenheim dropped their price objective on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. JPMorgan Chase & Co. cut their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. HSBC raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. Finally, Cantor Fitzgerald boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $28.61.

Pfizer Stock Down 0.6%

Shares of PFE opened at $27.82 on Friday. The firm has a 50 day simple moving average of $27.62 and a two-hundred day simple moving average of $26.49. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a one year low of $23.62 and a one year high of $29.21. The company has a market cap of $158.59 billion, a P/E ratio of 36.61, a P/E/G ratio of 1.88 and a beta of 0.32.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The company's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date is Friday, November 6th. Pfizer's payout ratio is currently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA expands TUKYSA opportunity: The FDA approved TUKYSA (tucatinib) with trastuzumab and pertuzumab as a frontline maintenance treatment for adults with unresectable or metastatic HER2-positive breast cancer. The expanded label moves the drug into an earlier treatment setting, potentially increasing its addressable market and supporting Pfizer’s oncology growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Promising pipeline developments: Positive Phase 3 results for LITFULO in nonsegmental vitiligo showed meaningful facial and total-body repigmentation with favorable tolerability. Pfizer plans regulatory submissions, which could broaden the drug’s immunology-market opportunity. Pfizer Posted Positive Phase 3 Vitiligo Results
• Positive Sentiment: Potential earnings support: Analysts note Pfizer’s history of earnings surprises and suggest the company currently has favorable conditions for another quarterly beat. Oncology product sales, biosimilars, and late-stage pipeline progress will be important ahead of third-quarter results. Will Pfizer Beat Estimates Again?
• Neutral Sentiment: Analyst target increase: Cantor Fitzgerald raised its price target from $27 to $28 while retaining a “neutral” rating, implying limited near-term upside and signaling that valuation and execution risks remain balanced. Cantor Fitzgerald Pfizer Price Target Update
• Negative Sentiment: Dividend and balance-sheet concerns: Pfizer declared a quarterly dividend of $0.43 per share, but commentary warns that the roughly 6% yield, frozen payout, debt, and a recent multibillion-dollar write-down may raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Restructuring and earnings pressure: Pfizer plans to cut about 330 jobs at its Sicily facility, while analysts describe an increasingly challenging period. The company’s cost reductions and recent loss per share underscore concerns about post-pandemic revenue declines and execution. Pfizer to Cut Around 330 Jobs in Italy

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.